
 [
{
"symbol" : "532908",
"exchange" : "BOM",
"id": "15755341",
"t" : "532908",
"e" : "BOM",
"name" : "Sharon Bio-Medicine Ltd."
, "f_reuters_url" : "http:\u002F\u002Fstocks.us.reuters.com\u002Fstocks\u002Fratios.asp?rpc=66\u0026symbol=",
"f_recent_quarter_date" : "",
"f_annual_date" : "",
"f_ttm_date" : "",
"financials" :
[{
"f_type" : "Income\u0026nbsp\u003BStatement"
,"url" : "http:www.google.comfinance?fstype=ii&q=BOM:532908"
,"f_figures" :
[
]
},
{
"f_type" : "Balance\u0026nbsp\u003BSheet"
,"url" : "http:www.google.comfinance?fstype=bi&q=BOM:532908"
,"f_figures" :
[
]
},
{
"f_type" : "Cash\u0026nbsp\u003BFlow"
,"url" : "http:www.google.comfinance?fstype=ci&q=BOM:532908"
,"f_figures" :
[
]
}],
"kr_recent_quarter_date" : "Q1 (Mar \u002716)",
"kr_annual_date" : "2016",
"kr_ttm_date" : "TTM",
"keyratios" :
[
{
"title" : "Net profit margin",
"recent_quarter" : "-429.81%",
"annual" : "",
"ttm" : ""
},
{
"title" : "Operating margin",
"recent_quarter" : "-301.98%",
"annual" : "",
"ttm" : ""
},
{
"title" : "EBITD margin",
"recent_quarter" : "",
"annual" : "",
"ttm" : ""
},
{
"title" : "Return on average assets",
"recent_quarter" : "-74.91%",
"annual" : "",
"ttm" : ""
},
{
"title" : "Return on average equity",
"recent_quarter" : "",
"annual" : "",
"ttm" : ""
}
]
, "c" : "-0.01",
"l" : "6.71",
"cp" : "-0.15",
"ccol" : "chr",
"op" : "7.05",
"hi" : "7.05",
"lo" : "6.50",
"vo" : "40,105.00",
"avvo" : "",
"hi52" : "10.10",
"lo52" : "4.98",
"mc" : "795.68M",
"pe" : "",
"fwpe" : "",
"beta" : "",
"eps" : "",
"dy" : "",
"ldiv" : "",
"shares" : "118.94M",
"instown" : "",
"eo":""
, "related" : [
{
"id" : "15755341",
"name" : "Sharon Bio-Medicine Ltd.",
"t" : "532908",
"e" : "BOM",
"l" : "6.71",
"c" : "-0.01",
"mc" : "795.68M",
"cp" : "-0.15",
"ccol" : "chr"
}
,
{
"id" : "288966775187151",
"name" : "Artemis Global Life Sciences Ltd",
"t" : "AGLSL",
"e" : "NSE",
"l" : "111.00",
"c" : "+5.35",
"mc" : "7.39B",
"cp" : "5.06",
"ccol" : "chg"
}
,
{
"id" : "666842744126268",
"name" : "Dr. Lal PathLabs Ltd",
"t" : "LALPATHLAB",
"e" : "NSE",
"l" : "912.00",
"c" : "+6.40",
"mc" : "75.63B",
"cp" : "0.71",
"ccol" : "chg"
}
,
{
"id" : "278695766156198",
"name" : "Aspira Pathlab \u0026 Diagnostics Ltd",
"t" : "540788",
"e" : "BOM",
"l" : "0.00",
"c" : "-11.32",
"mc" : "",
"cp" : "-100.00",
"ccol" : "chr"
}
,
{
"id" : "3438678",
"name" : "A D S Diagnostic Ltd",
"t" : "523031",
"e" : "BOM",
"l" : "11.34",
"c" : "0.00",
"mc" : "24.43M",
"cp" : "0.00",
"ccol" : "chb"
}
,
{
"id" : "797667913386077",
"name" : "Thyrocare Technologies Ltd",
"t" : "THYROCARE",
"e" : "NSE",
"l" : "628.90",
"c" : "+6.30",
"mc" : "33.28B",
"cp" : "1.01",
"ccol" : "chg"
}
,
{
"id" : "7268066",
"name" : "Auro Laboratories Ltd",
"t" : "530233",
"e" : "BOM",
"l" : "99.50",
"c" : "+0.95",
"mc" : "622.66M",
"cp" : "0.96",
"ccol" : "chg"
}
,
{
"id" : "2863687",
"name" : "Scandent Imaging Ltd",
"t" : "516110",
"e" : "BOM",
"l" : "18.50",
"c" : "+0.10",
"mc" : "593.85M",
"cp" : "0.54",
"ccol" : "chg"
}
,
{
"id" : "3900000",
"name" : "Smruthi Organics Ltd",
"t" : "540686",
"e" : "BOM",
"l" : "111.70",
"c" : "-2.80",
"mc" : "426.18M",
"cp" : "-2.45",
"ccol" : "chr"
}
,
{
"id" : "6985222",
"name" : "Triochem Products Ltd",
"t" : "512101",
"e" : "BOM",
"l" : "17.40",
"c" : "0.00",
"mc" : "4.12M",
"cp" : "0.00",
"ccol" : "chb"
}
,
{
"id" : "8321085",
"name" : "Godavari Drugs Ltd",
"t" : "530317",
"e" : "BOM",
"l" : "35.65",
"c" : "+1.65",
"mc" : "268.46M",
"cp" : "4.85",
"ccol" : "chg"
}
]
, "summary" : [{
"address": "C-312 BSEL Tech Park,, Sector 30(A),Vashi,, NAVI MUMBAI, 400703, India",
"phone": "+91-22-67944000",
"fax": "+91-22-67944001",
"url": "http:\u002F\u002Fwww.sharonbio.com\u002F",
"overview" : "Sharon Bio-Medicine Limited is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and commercialization of pharmaceutical products. The Company operates in three segments, which include Active Pharma Ingredients (API\u0027s), Formulations and Toxicology. The Company offers various Active Pharmaceutical Ingredients, including Ketoconazole, Trimetazidine Di HCI, Glimepiride, Eperisone HCI, Memantine HCI, Telmisartan, Nifedipine, Aripiprazole and Atomoxetine HCI. The Company offers various intermediate products, including Cis Bromo Benzoate, N-Acetyl-4(4-Hydroxy Phenyl) Piperazine, Cis Tosylate and Tri Ethyl Benzyl Ammonium Chloride. The Company also offers various services, including preclinical toxicology on small animals, chemical process development and scale up, formulation development, analytical method development, drug master file (DMF) and dossier preparation, and commercial manufacturing of intermediates, actives and finished dosages."
} ]
, "management" : [
{
"name" : "Savita Satish Gowda",
"title" : "Executive Chairman of the Board, Chief Executive Officer, Managing Director"
}
,
{
"name" : "Deepali Bhatia",
"title" : "Compliance Officer, Company Secretary"
}
,
{
"name" : "Lalit Misra",
"title" : "Whole-Time Director"
}
]
,"moreresources" : [
]
}]
